Table 3 Risk of AF progression in the original cohort and the matched cohort.

From: Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation

 

No. of patients with event

Event rate

HR (95% CI)

P

Before matching

 ARB

33

29.2%

Ref.

 

 ARNI

6

10.5%

0.34 (0.14, 0.81)

0.015

After matching

 ARB

17

36.2%

Ref.

 

 ARNI

5

10.6%

0.32 (0.12, 0.88)

0.016

  1. AF atrial fibrillation, ARB angiotensin receptor blocker, ARNI Angiotensin receptor- neprilysin inhibitor, HR hazard ratio, CI confidence interval.
Back to article page